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LETTER TO THE EDITOR
Does unified allergic airway disease impact 
on lung function and type 2 biomarkers?
Chris RuiWen Kuo, Rory Chan and Brian Lipworth* 
Abstract 
The concept of the unified allergic airway disease (UAD) recognises the association between allergic inflammation in 
the upper and lower airways. Patients with asthma and concomitant allergic rhinitis experience more asthma-related 
primary and secondary care visits. We therefore aimed to determine differences in asthma control (asthma control 
questionnaire ACQ-6), lung function (spirometry) and T2 biomarkers (FeNO and Eos) in relation to the presence of 
allergic rhinitis in patients with allergic asthma. Retrospectively, we evaluated a cohort of 60 consecutive patients with 
persistent asthma attending our research unit for screening into clinical trials. All included subjects were receiving 
inhaled corticosteroids (ICS) and had a positive skin prick test (SPT) to at least one common aeroallergen to fulfil 
the criterion of allergic asthma. Patients with UAD had a diagnosis of allergic asthma in addition to established 
concomitant allergic rhinitis. T2 biomarkers were significantly higher in patients with allergic rhinitis in contrast to 
those without.  FEV1 % predicted and  FEF25-75 % predicted were also significantly lower in patients with concomitant 
allergic rhinitis. However, there was no difference in ACQ-6 observed between groups. In summary, patients with 
allergic asthma, the presence of concomitant allergic rhinitis is associated with worse lung function and higher type 2 
biomarkers.
Keywords: Unified allergic airway disease, Asthma, Allergic rhinitis, Asthma control questionnaire, Fractional exhaled 
nitric oxide, Eosinophil, Spirometry
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To the Editor
The concept of the unified allergic airway disease 
(UAD) recognises association between allergic 
inflammation in the upper and lower airway. This in 
turn led to development of guidelines looking at allergic 
rhinitis and its impact on asthma [1]. Patients with 
asthma and concomitant allergic rhinitis experience 
more asthma-related primary and secondary care visits 
[2]. Clinical trials of intranasal steroids (INS) in patients 
with allergic rhinitis and asthma have demonstrated 
improvements in bronchial hyper-responsiveness to 
methacholine [3] suggesting that the upper airway 
may contribute downstream to asthma control. Indeed 
treatment with INS can reduce emergency room visits 
and hospitalisation for asthma [4].
To our knowledge, presently there are no studies 
looking at asthma control, lung function and type 
2 (T2) biomarkers such as fractional exhaled nitric 
oxide (FeNO) and blood eosinophils (Eos), which have 
compared allergic asthma patients with and without 
allergic rhinitis.
We therefore wished to see if there were differences in 
asthma control (as asthma control questionnaire ACQ-
6), lung function (as spirometry) and T2 biomarkers (as 
FeNO and Eos) in relation to the presence of allergic 
rhinitis in patients with allergic asthma.
Retrospectively, we evaluated a cohort of 60 
consecutive patients with persistent asthma meeting the 
criteria, who attended our research unit for screening 
into clinical trials. All asthmatic subjects included were 
receiving inhaled corticosteroids (ICS) and had a positive 
skin prick test (SPT) to at least one common aeroallergen 
in order to fulfil the criterion of allergic asthma. 
Patients with UAD had a diagnosis of allergic asthma 
in addition to an established diagnosis of concomitant 
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allergic rhinitis and were receiving therapy with INS 
with or without concurrent use of oral or intranasal 
antihistamine. Patients without allergic rhinitis were 
required to have no attributable perennial or seasonal 
nasal symptoms. Spirometry (Micromedical, Chatham, 
United Kingdom) was performed in triplicate. Caldicott 
guardian approval was obtained to allow access to the 
patient identifiable National Health Service data on 
blood Eos, and all patients consented for their screening 
data to be accessed. Comparisons for each outcome 
between groups were made by unpaired Student’s t test 
with alpha error set at 0.05 (2-tailed). Chi square test was 
conducted to assess differences within each aeroallergen 
of SPT in between groups. The mean difference and 95% 
confidence intervals (CIs) for differences are given for 
significant comparisons.
The overall mean age was 52  years, mean forced 
expiratory volume in 1  s  (FEV1) 88% predicted, mean 
ACQ-6 score of 1.0, and mean ICS dose (beclomethasone 
equivalent) of 660  µg. 30 subjects in each group were 
identified with a diagnosis of allergic asthma with and 
without allergic rhinitis. The median number of positive 
SPT to common aeroallergens was 2 in both groups. The 
percentage sensitisation to each aeroallergen comparing 
allergic asthma with and without allergic rhinitis 
respectively were as follows: grass mix 50% vs 47%, trees 
13% vs 13%, weeds 10% vs 3%, house dust mite 47% vs 
70%, Aspergillus fumigatus 10% vs 7%, feathers 0% vs 
3%, dog 33% vs 30% and cat 40% vs 57%. There were no 
significant differences within each aeroallergen between 
groups.
The characteristics of the study subjects and significant 
comparisons are summarised in Table  1. In the group 
with allergic rhinitis, Eos mean difference 148 (CI 48–247; 
p = 0.005) cells/µL and FeNO 21 (CI 7–35; p = 0.004) ppb 
were significantly higher than the group without allergic 
rhinitis (Fig.  1). The spirometry measurements were 
also significantly lower in patients with concomitant 
allergic rhinitis compared to those without, with  FEV1% 
predicted: − 8% (CI − 16% to − 0.17%; p = 0.045) and 
forced expiratory flow at 25% to 75% of forced vital 
capacity  (FEF25–75% predicted): − 16% (CI − 28% to − 4%; 
p = 0.008) (Fig.  1).  FEV1 in litres was also significantly 
lower in allergic rhinitis: − 0.44L (CI − 0.79L to − 0.09L); 
p = 0.016). However, there was no difference observed in 
ACQ-6 (p = 0.966) when comparing groups. There were 
no significant correlation between  FEV1 and  FEF25–75 vs 
FeNO in either group. 
Comparing our results to previous study, Gratziou 
et  al. [5] demonstrated that FeNO was significantly 
higher in patients with concomitant allergic asthma and 
rhinitis compared to non-allergic patients, although 
their study did not differentiate with regards to allergic 
asthma without concomitant allergic rhinitis. Our results 
showed that the T2 biomarkers were higher in the group 
with UAD despite the concomitant use of INS and ICS, 
with the mean ICS dose being approximately 200  µg 
higher than those without allergic rhinitis. However, a 
previous study has shown that blood eosinophil counts 
were significantly suppressed from corticosteroid naïve 
baseline by combined treatment with INS and ICS in 
patients with UAD [6]. Notably we found no difference 
in the number of positive skin prick tests between the 
two groups indicating that the allergic burden was 
comparable. Hence, the presence of rhinitis rather 
than allergen sensitisation per se in UAD is the most 
likely explanation for the observed results. The patients 
with UAD were taking a 29% higher dose of ICS which 
presumably reflects the disease burden.
A higher T2 burden mirrored poorer lung function 
in the patients with UAD. In our study, the mean 
difference in  FEV1 between groups exceeded the 
minimal clinically important difference of 230 ml. This 
supports the presence of cross-talk between upper and 
lower airway mucosa in response to allergy related T2 
inflammation in UAD. High T2 biomarkers especially 
blood eosinophils are associated with more severe 
asthma [7]. In severe persistent asthma with high T2 
Table 1 Characteristics of  the  study subjects 
and significant comparisons
ICS as beclomethasone equivalent dose
LABA long acting β2 agonist, LAMA long acting muscarinic antagonist, LTRA 
leukotriene receptor antagonist, THEO theophylline, OAH oral antihistamine, INS 
intranasal steroid, INAH intranasal antihistamine
Values are presented as mean (SEM), †median (IQR). *p < 0.05, **p < 0.01
Allergic asthma 
with allergic rhinitis
Allergic asthma 
without allergic 
rhinitis
Age 55 49
F/M 17/13 11/19
SPT† 2 (1–4) 2 (1–3)
ICS (µg) 750 580
LABA 70% 63%
LAMA 23% 10%
LTRA 43% 17%
THEO 3% 3%
OAH 53% 0
INS 100% 0
INAH 7% 0
ACQ-6 1.03 (0.13) 1.04 (0.17)
FEV1 (% predicted) 84 (3) 92 (3)*
FEF25–75 (% predicted) 43 (4) 59 (5)**
FeNO (ppb) 50 (6) 29 (4)**
Eos (cells/µL) 380 (34) 233 (36)**
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biomarkers, biologic therapies directed at IL-5 and 
IL-13 result in lower circulating levels of eosinophils 
and immunoglobulin E, which in turn reduces asthma 
exacerbations [8, 9].
A previous study in children revealed that the 
presence of allergic rhinitis was associated with 
worse asthma control in terms of paediatric ACQ 
[10]. Conversely, our study has shown no significant 
difference in ACQ comparing the two groups. This may 
reflect the high proportion of patients on second line 
controller therapy in patients with UAD.
We appreciate that there are limitations to our study. 
Firstly, we used retrospective cross-sectional data and 
hence prospective evaluation might be able to further 
evaluate the influence of UAD and associated therapies 
over time. Secondly, since ACQ represents a snapshot of 
the previous week, it is conceivable that if prospective 
consecutive evaluation had been performed then we 
might have shown worse asthma control in patients 
with UAD. Thirdly, since our patients were volunteers 
who self-selected to be included into clinical trials, we 
could have been open to some sort of selection bias—
in other words our data might not be representative 
of the wider asthma population in real life. Finally, we 
had no measures of allergic rhinitis such as total nasal 
symptom score or peak nasal inspiratory flow rate.
In summary, we have shown evidence to support 
the concept of unified allergic airway disease by 
demonstrating that in patients with allergic asthma, the 
presence of concomitant allergic rhinitis is associated 
with worse lung function and higher type 2 biomarkers. 
We therefore emphasise the importance of recognising 
the presence of concomitant allergic rhinitis and 
incorporating an algorithm combining type 2 biomarkers 
and lung function in assessing asthma patients.
Abbreviations
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